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Introduction
!
Gastric ulceration is a common worldwide prob-
lem which can often lead to dyspeptic symptoms,
epigastric pain, gastrointestinal bleeding and/or
anemia. While Helicobacter pylori is commonly
implicated in the pathogenesis of benign ulcera-
tion [1], the risk of malignant change in gastric ul-
cer has long been recognized [2]. In the literature,
the rate of malignancy in endoscopically diag-
nosed gastric ulcers varies considerably, ranging
from 2.4–21% [3,4].
Subsequently there has been disagreement over
the requirements for follow-up in patients with
gastric ulcers. A number of studies have reported
low rates of additional gastric cancer diagnoses
when following up patients with gastric ulcers
[3,5]. This was especially the case if initial histol-
ogy showed benign features and if no endoscopic
suspicion was raised [5].
The discrepancy in study findings and research-
ers’ opinions has also translated into international
guidelines. The British National Institute for
Health and Care Excellence (NICE) recommends a
follow-up endoscopy (FU-OGD) for every patient
with a gastric ulcer 8 weeks after index endos-
copy [6,7]. In contrast, the American Society for
Gastrointestinal Endoscopy recommends follow-
up endoscopy only for selected cases of gastric ul-
cers [8]. Neither guideline advises on the need for
biopsies of gastric ulcers at index endoscopy or
follow-up.
The aim of this study was to determine the malig-
nancy yield in gastric ulcers in a British setting,
assess the impact of NICE guidance, and establish
predictive factors potentially allowing a more tar-
geted follow-up program.
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Background and study aim:Malignant change can
occur in gastric ulcer but guideline recommenda-
tions for follow-endoscopy (FU-OGD) are conflict-
ing. This study aims to determine rate of malig-
nancy and need for follow-up for gastric ulcers.
Patients and methods: Patients with a first diag-
nosis of gastric ulcer between January 2012 and
September 2013 were studied by analyzing endo-
scopic assessments, dysplasia, and malignancy
yield and the influence of risk factors on the like-
lihood of benign disease.
Results: In a cohort of 432 patients with gastric
ulcer (53% male, mean age 65 years) dysplasia or
neoplasia were found in 27 (19 adenocarcinomas,
2 cases of dysplasia, 5 lymphomas, 1 melanoma;
malignancy yield 6%). Twenty-five (93%) cases
were diagnosed on first biopsy. The cancer yield
of FU-OGD after initially benign biopsy was 0.9%.
Binary logistic regression analysis revealed that
endoscopically benign appearance (odds ratio
0.004 95% CI 0–0.576; P=0.029), benign histolo-
gy on first biopsy (odds ratio 0 95% CI 0–0.39; P=
0.011) and lower number of ulcers (odds ratio
0.22 (95% CI 0.05–0.99); P=0.049) were indepen-
dent predictors of benign disease. All dysplastic
and neoplastic cases would have been identified
by a combination of initial biopsies plus repeat
endoscopy with further biopsies for endoscopi-
cally suspicious appearances.
Conclusions: In this large cohort 6% of gastric ul-
cers were found to be malignant, highlighting the
need for all gastric ulcers to be biopsied. The can-
cer yield of FU-OGD after benign biopsies was
low. We have demonstrated that the combination
of benign index histology and no endoscopic sus-
picion of malignancy can predict benign disease.
We recommend that all gastric ulcers to be biop-
sied. Risk stratification could potentially reduce
need for FU-OGD.
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Patients and methods
!
Leeds Teaching Hospitals NHS Trust is the main secondary care
provider for a population of 770,000. The endoscopy department
operates 10 endoscopy rooms at 3 sites performing approximate-
ly 20,000 procedures per annum.
For this study we searched gastroscopy records within the elec-
tronic endoscopy reporting system (ADAM, Fujifilm Europe
GmbH, 2011) and included all patients with a first endoscopic di-
agnosis of gastric ulcer between January 2012 and September
2013. Patients with known gastric ulcers prior to the study peri-
od or those referred for tertiary assessment were excluded. Pa-
tient demographics, data on endoscopic appearance and histolo-
gical reports were recorded from ADAM and the electronic pa-
tient record system. Endoscopy procedures were performed by a
group of certified endoscopists comprising gastroenterologists,
surgeons, trainees, and nurse endoscopists. Gastric ulcers were
defined as a mucosal break of 5mm or larger in diameter with
unequivocal depth, and erosion by mucosal change with white
necrotic substance [9].
The primary analysis of the whole study cohort included analysis
of endoscopic assessments, compliance with NICE guidance, and
the overall combined dysplasia and malignancy yield. To assess
compliance with required service standards we analyzed the
proportion of FU-OGD performedwithin 8 weeks of index endos-
copy (national standard) and the number of FU-OGD performed
within 2 weeks of index endoscopy if no biopsies were taken (lo-
cally agreed standard).
For the secondary analysis of predictors of benign and malignant
disease, we excluded patients with insufficient follow-up to en-
sure that no patient with a potential malignant transformation
within 1 year was classified as benign disease. Insufficient fol-
low-up was therefore defined as the lack of follow-up endoscopy
and lack of data within the medical records to ascertain cancer-
free survival of at least 360 days. Neoplastic disease was defined
as histologic evidence of gastric dysplasia or malignancy.
Benign disease was defined as patients with complete ulcer heal-
ing, those with at least 2 sets of benign biopsies and no endo-
scopic suspicion of malignant disease, or in cases without FU-
OGD, 1 set of negative biopsies and at least 360 days cancer-free
survival. Patients with insufficient follow-up (as judged by the
above criteria) were excluded from the secondary analysis.
Endoscopic ulcer appearance was recorded from the endoscopy
reports. Ulcers were classified as superficial, cratered or linear,
which are the preset classification criteria on the endoscopy re-
porting system. The endoscopist’s subjective impression was re-
corded dichotomously (suspicious appearance/non-suspicious
appearance) by analysing the free text comment on the endos-
copy reports (if suspicious features were not documented the ul-
cer was classed as showing “non-suspicious appearance”).
We analyzed the influence of demographic, endoscopic, and his-
tologic factors on the likelihood of benign disease using chi-
square test for categorical and t-test for continuous variables. In-
dependence of variables was analyzed by entering variables
showing statistical significance on univariate analysis into binary
logistic regression analysis. The Hosmer-Lemeshow’s test was
used to test the null hypothesis that there was a linear relation-
ship between predictor variable and the log odds of the outcome
variable. Correlation matrices were used to identify collinearity.
If collinearity was detected we planned to minimize this by in-
putting the variable separately in the multivariate analysis. All
statistical tests were done using PASW version 21 (IBM Corp, NY).
The study was performed as a clinical audit of routinely collected
patient data. Clinical audits are exempt from the need of ethics
committee approval and the need for written informed consent
under UK regulations [10].
Results
!
The primary analysis cohort consisted of 432 patients (53%male)
with a mean age of 65 years (●" Table1). The presenting feature
leading to endoscopy was a gastrointestinal bleed in 38%, anae-
mia in 13%, dyspepsia in 18% and other symptoms (including
weight loss or any combination of symptoms) in 31%.
No biopsies were taken in 142 patients at index endoscopy as 73%
of these had presented with a gastrointestinal bleed (●" Fig.1)
and 6% were fully anticoagulated at the time of endoscopy. In
21% no reason to withhold biopsies was given. Of these 142, 67%
(96 patients) received a FU-OGD for biopsies after a median of 7
days (range 1–363 days, interquartile range 3–38 days). No FU-
OGD occurred in 46 of these cases.
Two hundred and ninety patients had an average of 4.8 biopsies
taken on index endoscopy. Of these, 194 underwent FU-OGD
after a median of 70 days (range 3–639 days, interquartile range
52–108 days). Only 33% underwent FU-OGD within the recom-
mended time frame of 8 weeks. Reasons for not undergoing FU-
OGD included failure to request the procedure by the medical
team in 10%. A repeat procedure was deemed medically inap-
propriate (comorbidities, life expectancy, etc) by the clinical
team in a further 19%. Twelve percent of patients died before
Table 1 Patient characteristics and index endoscopy features.
Age Mean 65 years
46 aged≤40 years
386 aged > 40 years
Sex 229 male (53%)
203 female (47%)
Presenting features 164 gastrointestinal bleed (38%)
56 anaemia (13%)
78 dyspepsia (18%)
134 other symptoms (31%)
First biopsy 290 on index endoscopy (mean 4.8 samples)
142 patients not biopsied initially
– 73% gastrointestinal bleed
– 6% anticoagulation
– 21% no reason
Number of ulcers on
index endoscopy
1 ulcer: 289 patients (67%)
2 ulcers: 39 patients (9%)
3 ulcers: 26 patients (6%)
More than 3 ulcers: 78 patients (18%)
Size of largest ulcer on
index endoscopy
Mean size 11mm
148 patients with largest ulcer≥10mm
284 patients with largest ulcer < 10mm
Morphology of ulcers
on index endoscopy
Superficial: 172 patients (49%)
Cratered: 162 patients (38%)
Other/not documented: 98 patients (23%)
Ulcer location Antrum: 251 patients (58%)
Body: 75 patients (17%)
Fundus / GOJ: 46 patients (11%)
Other / not documented: 60 patients (14%)
Helicobacter pylori
status
Positive 78 (18%)
Negative 202 (47%)
Not tested for 152 (35%)
Endoscopically suspi-
cious appearance
Yes: 33 patients (8%)
No: 399 patients (92%)
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the FU-OGD was due. Other reasons for a lack of FU-OGD includ-
ed patient non-attendance (24%) and malignant disease on first
biopsy (9%). There was no recorded reason in 26%.
FU-OGD occurred overall in 290 patients. Complete ulcer healing
was documented endoscopically in 236 patients. Gastric neopla-
siawas found in 27 patients (19 adenocarcinomas, 2 cases of low-
grade dysplasia [11], 5 lymphomas, 1 melanoma) leading to a di-
agnosis of malignancy in 6% of patients with gastric ulcers
(●" Fig.1). Of these, 25 (93%) were diagnosed on first biopsy.
Three hundred and fifty-eight patients were at least biopsied
once during the study. After excluding patients with dysplasia or
malignancy on first biopsy (n=25), without biopsies on repeat
endoscopy (n=28), and those without sufficient follow-up and/
or no further endoscopy after index biopsy (n=80), the cancer
yield of FU-OGD after initially benign biopsy was 2 of 225 pa-
tients (0.9%). No cases of gastric cancer were detected in the
group of patients without FU-OGD.
After excluding those patients with insufficient follow-up (as
outlined in the methods section) the cohort for the secondary a-
nalysis consisted of 377 patients. Of these, 350 (92%) had benign
disease and 27 had dysplastic or neoplastic disease. Patient sex,
indication for gastroscopy, and H pylori status did not influence
the likelihood of benign disease. Benign disease was significantly
associated (●" Table 2) with ulcer location in the antrum (P=
0.001), endoscopic benign appearance as judged by the endos-
copist at the time of procedure (●" Fig.2, P<0.001), non-cratered
ulcer morphology (●" Fig. 3, P<0.001), benign histology on first
biopsy (P<0.001), younger age (mean 64 vs 73 years, P=0.02),
lower number of ulcers (mean 1.4 vs 2, P<0.001), and smaller ul-
cer size (mean 10 vs 28mm, P<0.001). The number of biopsies
taken was not associated with the likelihood of benign or malig-
nant disease.
After binary logistic regression analysis, endoscopic benign
appearance (odds ratio 0.004 95%CI 0–0.576; P=0.029), benign
histology on first biopsy (odds ratio 0 95% CI 0–0.39; P=0.011),
and lower number of ulcers (odds ratio 0.22 (95% CI 0.05–0.99);
P=0.049) were independent predictors of benign disease (●" Ta-
ble2). To rule out selection bias by including patients without
FU-OGD, these patients were compared to those with FU-OGD
and benign disease. Those without FU-OGD had significantly
fewer biopsies (mean 4.59 vs 5.14; P=0.023) and were more like-
ly to have presentedwith “other symptoms” rather than a gastro-
intestinal bleed (P=0.001). No differences in age, number of ul-
cers, ulcer size, location, or macroscopic or histologic appearance
were found. No significant collinearity was detected on correla-
tion matrices and the Hosmer-Lemeshows test was not signifi-
cant, suggesting that the data fit the model well.
All dysplastic and neoplastic cases would have been correctly
identified if a combination of at least 1 set of biopsies for all ulcers
and repeat endoscopy with further biopsies for patients with ul-
432 patients in cohort
142 no biopsy on index endoscopy 290 biopsied on index 
endoscopy
46 no follow up endoscopy 96 FU-OGD for biopsy 386 patients who were biopsied
25 cases of dysplasia 
or neoplasia on index 
biopsy
2 cases of neoplasia on 
repeat biopsy
Fig.1 Patient flow in the study cohort.
Table 2 Predictors of benign disease.
Predictor Univariate analysis Multivariate analysis Odds ratio (logistic
regression analysis) with 95% CI
P value (logistic regression
analysis)
Ulcer location in the antrum P=0.001 0.1 (0.003–3.228) P=0.194
Endoscopically benign appearance P < 0.001 0.004 (0–0.576) P=0.029
First biopsies benign P < 0.001 0.0 (0.00–0.39) P=0.011
Younger age (mean) 64 vs 73 years, p = 0.02 1.039 (0.938–1.150) P=0.466
Lower number of ulcers (mean) 1.4 vs 2
P < 0.001
0.22 (0.05–0.99) P=0.049
Smaller ulcer size (mean) 10 vs 28mm
P < 0.001
0.992 (0.933–1.055) P=0.802
397 endoscopically benign ulcers
10 cancer/dysplasia 
on biopsy 387 benign disease
35 endoscopically suspicious ulcers
17 cancer/dysplasia 
on  biopsy 18 benign disease
Fig.2 Outcomes stratified by endoscopic and his-
tologic appearance.
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cers displaying suspicious features on index endoscopy had been
applied.
Discussion
!
Medical opinion and international guidelines on the appropriate
follow-up for patients with gastric ulcers remain divided. While
British guidelines mandate FU-OGD for all patients [6,7], the
American position of the ASGE advises that it is only required in
selected cases [8]. In this large cohort of patients, it was demon-
strated that gastric ulcers are associated with a significant risk of
dysplasia or malignancy of 6%. The major strength of this study is
the non-selected secondary care cohort of patients thus reducing
selection bias, whichmay explain thewide variation of malignan-
cy rates reported in previously published case series. The large
size of the cohort also allows for accurate determination of fac-
tors predicting benign or malignant disease. Furthermore, the
endoscopies were performed by a diverse group of endoscopists
rather than purely tertiary referral expert endoscopists.
The need for biopsies of all gastric ulcers has so far not been re-
cognized by international guidelines. In this study 90% of cases of
dysplasia or neoplasia were diagnosed with first biopsy, high-
lighting the need for all gastric ulcers to be biopsied. This is espe-
cially important as a number of ulcers with neoplasia on histolo-
gy did not show endoscopically suspicious features. It follows
that all gastric ulcers should be biopsied with an appropriate
number of samples (at least 4) reflecting the ulcer size. The num-
ber of biopsies taken was not associated with the likelihood of
malignant disease in this study, but a number of studies have sug-
gested that 3 to 4 biopsy samples are usually sufficient to diag-
nose cancer in gastric ulcers with 95% sensitivity [12,13]. The
sensitivity reached 100% when 7 samples were obtained [13]. If
biopsies cannot be performed on index endoscopy (because of
anticoagulation, gastrointestinal bleeding, etc), a repeat proce-
dure for biopsies should be scheduled at the earliest opportunity
to avoid delays in a potential diagnosis of neoplasia.
This study also highlighted that for many patients, FU-OGD was
deemed inappropriate due to comorbidities and patient frailty.
This is also reflected in the number of patients who died before
a follow-up procedure was due. Gastric ulcers are often found in
patients who have acute severe illnesses or are elderly with mul-
tiple medical issues. In such circumstances the need for FU-OGD
needs to be balanced against overall life expectancy and the po-
tential suitability for definitive treatment if a gastric malignancy
were found. The high non-attendance rate noted in this study
may relate to the uncomfortable and invasive nature of endos-
copy. Furthermore patients may have not have been made aware
of the reasons for FU-OGD and the implications of non-atten-
dance.
We have demonstrated in this study that early FU-OGD for biop-
sies in those with no initial biopsies can be achieved in a very
busy endoscopy department. Unfortunately many patients
waited longer than the recommended 8 weeks after initial be-
nign biopsies for a FU-OGD. However, the cancer yield of FU-
OGD after benign biopsies remains low. Strategies to reduce the
burden of FU-OGD for both patients and the health service would
therefore be highly desirable.
We have demonstrated that several simple factors collected dur-
ing index endoscopy and ulcer biopsy can predict benign disease.
Risk stratification using the endoscopist’s impression of the gas-
tric ulcer and initial biopsy identified all cases of neoplasia in this
study. It thereforemay be that the need for FU-OGD in all patients
with benign endoscopy and histology should be reconsidered.
These data are supported by experience from another center [5]
and suggest that the need for FU-OGDmay not need to be a blan-
Fig.3 Ulcer morphology. a Superficial ulcers. b Linear ulcer. c Cratered ulcer. d Rolled edges and mucosal irregularity. e Rolled edges and protrusion into the
lumen.
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ket approach for all gastric ulcers but would benefit from evalua-
tion of individual patient risk factors.
There are a number of limitations to our study. While this is a
large study, all of the patients came from 1 geographical area in
Northern England. Case identification via the endoscopy report-
ing system allowed capture of all cases of gastric ulcers as these
were entered prospectively on the reporting system. Data collec-
tion, however, used retrospective methodology by examining
endoscopy reports and medical and histology records. Conse-
quently we were unable to examine the influence of other pre-
senting features, particularly weight loss. Furthermore the
endoscopist’s overall impression of a gastric ulcer was taken
from endoscopists’ comments in the report’s free comment
boxes. This method introduces a large degree of subjectivity, but
the use of free text is a matter of routine in endoscopy reporting
practice. Lesion identification and characterization is a key part
of endoscopy training, yet such training often varies in different
institutions. It is therefore possible that the practice of endos-
copists may vary between different locations. Importantly and
in contrast to other studies, this one did not rely on the impres-
sion of tertiary referral expert endoscopists. This highlights that
endoscopic interpretation by any JAG-certified endoscopist was
sufficiently accurate for differentiation between suspicious and
non-suspicious appearance.
This study is also limited in that a number of risk factors for gas-
tric cancer could not be addressed. Ethnicity can influence the
risk of gastric cancer and Japanese race is associated with an in-
creased risk [14,15]. Our study did not record the patient’s ethni-
city. However, fewer than 37,000 people of Japanese origin reside
in the UK (0.06% of the general population) [16] and it is unlikely
that Japanese ethnicity would have influenced our results. H py-
lori is an independent risk factor for gastric malignancy [17,18].
Unfortunately, H pylori status was not documented for some pa-
tients and our results should be interpretedwith cautionwith re-
gard to that status. Other risk factors such as atrophic gastritis
were not included in our analysis as no biopsies were obtained
from non-ulcerated areas of the stomach in accordancewith local
histopathology guidelines. Furthermore no data on medication
usage especially on Aspirin or nonsteroidal anti-inflammatory
drugs were available.
For this study the authors chose to report a combined outcome of
dysplasia and malignancy. In clinical practice it is of utmost im-
portance for the endoscopist to differentiate benign from poten-
tially malignant (ie dysplastic) and malignant disease. Hence dif-
ferentiation between clearly benign and the combined outcome
of dysplastic/neoplastic disease was considered clinically more
relevant. The number of dysplasia cases was too small to allow
for separate analysis. The study identified predictors of benign
versus malignant disease (rather than malignant versus benign)
and therefore promotes the identification of benign disease
which may not require close follow-up. Ideally all of our patients
should have undergone FU-OGD but it was important to report
on the full cohort rather than just selecting those with FU-OGD.
The authors included patients without FU-OGD who survived
more than 360 days without a cancer diagnosis in the group of
patients with benign disease. Given the fast-growing nature of
upper gastrointestinal malignancies, the authors opine that this
is a clinically justified characterization. Because this group of pa-
tients differed from those with FU-OGD only marginally (the nu-
meric differences in number of biopsies obtained are of doubtful
clinical importance), that is unlikely to influence the outcome of
our analysis. In Japanese cohorts very early-stage cancers and
dysplasia may be slowly progressive and it would be possible,
but unlikely, to have missed such cases through the 360-day fol-
low-up period [19]. However, all our patients presented with
symptoms in the first instance, whereas in Japanese patients, de-
tection was usually through screening and they would have been
asymptomatic. Because median survival from gastric cancer is
unfortunately only 35 weeks in the United Kingdom [20], the
choice of 360-day follow-up is very unlikely to influence the out-
comes or our conclusions.
This study has demonstrated a 6% combined dysplasia andmalig-
nancy risk in gastric ulcers. Biopsies of all gastric ulcers should be
performed as a matter of routine and, if not possible, at time of
first endoscopy, should be scheduled as soon as possible after-
wards. However, routine FU-OGD may not be required for all pa-
tients with gastric ulcers, as a combination of benign endoscopy
appearance and benign histology accurately predicted benign
disease in this study.
Competing interests: None
References
1 Kuipers EJ, Thijs JC, Festen HP. The prevalence of Helicobacter pylori in
peptic ulcer disease. Aliment Pharmacol Ther 1995; 9: (Suppl 02) 59–
69
2 Bustamante M, Devesa F, Borghol A et al. Accuracy of the initial endo-
scopic diagnosis in the discrimination of gastric ulcers: is endoscopic
follow-up study always needed? J Clin Gastroenterol 2002; 35: 25–28
3 Lv SX, Gan JH,Ma XG et al. Biopsy from the base and edge of gastric ul-
cer healing or complete healing may lead to detection of gastric cancer
earlier: an 8 years endoscopic follow-up study. Hepatogastroenterol
2012; 59: 947–950
4 Amorena Muro E, Borda Celaya F,Martínez-Peñuela Virseda JM et al. [A-
nalysis of the clinical benefits and cost-effectiveness of performing a
systematic second-look gastroscopy in benign gastric ulcer]. Gastroen-
terol Hepatol 2009; 32: 2–8
5 Mañas MD, Domper A, Albillos A et al. Endoscopic follow-up of gastric
ulcer in a population at intermediate risk for gastric cancer. Rev Esp
Enferm Dig 2009; 101: 317–324
6 National Institue for Health and Care Excellence. Dyspepsia: Manage-
ment of dyspepsia in adults in primary care. In: excellence NIfHaC
(ed) NICE clinical guideline 17; 2004
7 National Institue for Health and Care Excellence. Dyspepsia and gastro-
oesophageal reflux disease. NICE clinical guideline 184; 2014
8 Banerjee S, Cash BD, Dominitz JA et al. The role of endoscopy in the
management of patients with peptic ulcer disease. Gastrointest Endosc
2010; 71: 663–668
9 Uemura N, Sugano K, Hiraishi H et al. Risk factor profiles, drug usage,
and prevalence of aspirin-associated gastroduodenal injuries among
high-risk cardiovascular Japanese patients: the results from theMAGIC
study. J Gastroenterol 2014; 49: 814–824
10 [Anonymous]. Defining Research. In: Health Research Authority; Lon-
don: 2009
11 Schlemper RJ, Riddell RH, Kato Y et al. The Vienna classification of gas-
trointestinal epithelial neoplasia. Gut 2000; 47: 251–255
12 Choi Y, Choi HS, Jeon WK et al. Optimal number of endoscopic biopsies
in diagnosis of advanced gastric and colorectal cancer. J Korean Med
Sci 2012; 27: 36–39
13 Graham DY, Schwartz JT, Cain GD et al. Prospective evaluation of biopsy
number in the diagnosis of esophageal and gastric carcinoma. Gastro-
enterology 1982; 82: 228–231
14 Naylor GM, Gotoda T, Dixon M et al. Why does Japan have a high inci-
dence of gastric cancer? Comparison of gastritis between UK and Japa-
nese patients Gut 2006; 55: 1545–1552
15 Namekata T,Miki K, KimmeyM et al. Chronic atrophic gastritis and He-
licobacter pylori infection among Japanese Americans in Seattle.
American journal of epidemiology 2000; 151: 820–830
16 [Anonymous]. 2011 Census: Population Estimates for the United King-
dom. In: Statistics OfN (ed). London: 2011
Selinger Christian P et al. Follow-up endoscopy for gastric ulcers… Endoscopy International Open 2016; 04: E709–E714
Original article E713
THIEME
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
17 Yeh JM, Ho W, Hur C. Cost-effectiveness of endoscopic surveillance of
gastric ulcers to improve survival. Gastrointest Endosc 2010; 72: 33–
43
18 Wu CY, Kuo KN, Wu MS et al. Early Helicobacter pylori eradication de-
creases risk of gastric cancer in patients with peptic ulcer disease. Gas-
troenterology 2009; 137: 1641–1648
19 Tsukuma H, Oshima A, Narahara H et al. Natural history of early gastric
cancer: a non-concurrent, long term, follow up study. Gut 2000; 47:
618–621
20 Devane C. Living after diagnosis: Median cancer survival times. In:
Macmillan Cancer Support as accessed on 13/01/2016. http://www.
macmillan.org.uk/Documents/AboutUs/Newsroom/LivingAfterCan-
cerMedianCancerSurvivalTimes.pdf
Selinger Christian P et al. Follow-up endoscopy for gastric ulcers… Endoscopy International Open 2016; 04: E709–E714
Original articleE714
THIEME
Th
is
 d
oc
um
en
t w
as
 d
ow
nl
oa
de
d 
fo
r p
er
so
na
l u
se
 o
nl
y.
 U
na
ut
ho
riz
ed
 d
ist
rib
ut
io
n 
is 
st
ric
tly
 p
ro
hi
bi
te
d.
